Laurus Labs, a major player in the pharmaceutical and biotechnology space, has been gaining traction among investors due to its strong fundamentals and sectoral potential.
KRChoksey has downgraded its stance on Laurus Labs to "ACCUMULATE" from "BUY," with a revised target price of Rs 489, implying a modest 5.4% upside from the current price of Rs 464.
Laurus Labs' share price surged by 4%, trading at Rs 510.5, reflecting a broader rally in Indian pharmaceutical stocks following the U.S. House of Representatives' passing of the Biosecure Act.
Market expert Arman Nahar has suggested two BUY Calls and two SELL Calls for today’s trading session. Indian markets are expected to open slightly positive today.
